Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting — Multiple Myeloma Edition

Featuring perspectives from Dr Jacob Laubach, including the following topics: Evolution of first-line treatment for multiple myeloma (MM) (0:00)  Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27) ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35) ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57) ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05) ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33) Bispecific antibody therapy administration and patient education (52:41) ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17) CME information and select publications

Om Podcasten

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.